Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, is excited to announce the launch of its third and largest fund of $200 M. Fund III will be deployed to support and empower groundbreaking life sciences and medical technology companies aiming to drive innovation and improve patient outcomes. (PR)
Oaktree Capital Management, L.P. Is Betting on Life Sciences With $2.3-Billion Fundraise. This is the firm’s first dedicated life sciences fund. Non-dilutive financing said to be attractive for growing firms (bloomberg)
Arboretum Ventures Exceeds Target With $268 M Sixth Fund. Arboretum’s More Than Sixty Investments In Medical Devices, Diagnostics, Life Science Tools, And It‐enabled Healthcare Services Have Impacted Over 16 M Patients Nationwide. These Investments Have Spanned A Diverse Set Of Disease Areas Including Oncology, Cardiovascular, Infectious Disease, Pulmonology, Urology, And Orthopedics (Pr)
Life sciences VC firm Westlake Village BioPartners® is ready to restock its capital reserves shortly after its success with bringing portfolio company Acelyrin to one of the biggest IPOs in recent biotech memory (endpts)
UK Government ‘to unlock £75bn pension fund capital for startups’. Tech and investment community reacts to Chancellor Jeremy Hunt’s plan after nine funds agree to invest at least 5% into startups and scaleups (businesscloud)
Camena Bioscience Closes $10m Series A Financing as Demand for DNA Synthesis Technology Increases. Funding will be used to scale operations and continue the development of its pioneering DNA synthesis platform, gSynth™ (PR)
Akeso Therapeutics, Inc. has been awarded a SBIR Phase I grant of $398,040 from the National Cancer Institute of the NIH. This award will support our preclinical development of chimeric antigen receptor (CAR)-modified invariant Natural Killer T (iNKT) cell therapy for hematological malignancies.
The public-private consortium will fund three gene therapy clinical trials at UT Southwestern Medical Center and Children's Health. Two new gene therapy trials at UT Southwestern and Children’s Health funded through the consortium will test treatments for multiple sulfatase deficiency and Charcot-Marie-Tooth disease type 4J.(PR)